Cargando…
Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio
Institutional review boards (IRB) normally require of a morally defensible clinical trial that any trial participant will benefit from the inquiry, or at least not be exposed to a significant risk of having their prospects worsened by participating. Stage 1 HIV cure trials tend not to meet this requ...
Autor principal: | Kumar, Rahul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293851/ https://www.ncbi.nlm.nih.gov/pubmed/27590492 http://dx.doi.org/10.1136/medethics-2015-103127 |
Ejemplares similares
-
The social value of candidate HIV cures: actualism versus possibilism
por: Brown, Regina, et al.
Publicado: (2017) -
Must research benefit human subjects if it is to be permissible?
por: Wikler, Daniel
Publicado: (2017) -
An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research
por: Evans, David
Publicado: (2017) -
For love and money: the need to rethink benefits in HIV cure studies
por: Largent, Emily
Publicado: (2017) -
Sufficient Reasons to Act Wrongly: Making Parfit’s Kantian Contractualist Formula Consistent with Reasons
por: Gunnemyr, Mattias
Publicado: (2016)